Close Menu

NEW YORK – For breast cancer patients with ductal carcinoma in situ, clinicians generally have used tumor size and grade to determine treatment options, but PreludeDx has worked to provide a more precise and comprehensive option for these patients. 

Radiomics firm PreludeDx's DCISionRT test can determine the benefits of radiation therapy in patients with DCIS and is intended to help radiology oncologists and surgeons pinpoint the best course of action for a patient and better personalize treatment.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.